Wire · opportunities
Nogapendekin Alfa/BCG Shows 84% Cystectomy-Free Survival at 3 Years
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 October 2026 · Fusion42 review
Long-term data from the QUILT-3.032 trial shows nogapendekin alfa inbakicept combined with BCG achieves an 84% cystectomy-free survival rate at 3 years in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), supporting durable complete responses and bladder preservation. The FDA initially approved this treatment in 2024 and expanded its label in 2026 to include high-grade papillary-only tumors, reflecting its sustained efficacy and favourable safety profile.
This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it between 14 Oct 2026 and 19 Oct 2026.
◆ ◆ The Wire takeaway
Bladder cancer treatment just gained a durable, FDA-backed option reducing the need for cystectomy. If you build therapies or care pathways for bladder cancer, this shifts patient options and market dynamics in your favour.
◆ Coverage
1 source · first reported 14 Oct 2026 · latest 19 Oct 2026
◆ Related on Wire
◆ Topics